Abbott reports Q1 earnings, completes Exact Sciences acquisition

Abbott reported Q1 adjusted EPS of $1.15, up 6% year over year, on sales of $11.16 billion, up 7.8% reported and 3.7% comparable. The company reiterated solid 2026 guidance, forecasting comparable sales growth of 6.5% to 7.5% and adjusted EPS of $5.38 to $5.58, while factoring in $0.20 of dilution from the completed Exact Sciences acquisition. Abbott also raised its dividend to $0.63 per share quarterly and highlighted segment strength in Medical Devices and Established Pharmaceuticals, though Nutrition remained a drag.

Analysis

ABT’s print is less about the quarter and more about the shape of the next 12 months: the company is effectively resetting the growth algorithm by layering acquisition-driven revenue on top of already-healthy device momentum. The key second-order effect is mix: higher-growth medical devices and diabetes offset the slower nutrition franchise, so margins should be less fragile than headline segment dispersion suggests, even with the acquisition dilution.

The market may be underappreciating how much of the near-term skepticism is already in the stock. At ~20% off highs, ABT is trading like a defensive ex-growth healthcare name, while the guidance implies mid-to-high single-digit top-line growth with a credible path to reacceleration if the Exact Sciences integration goes smoothly. The biggest upside catalyst is not the current quarter but whether management can prove incremental operating leverage from cancer diagnostics over the next 2-3 quarters, which would force multiple expansion.

The main risk is that the merger introduces temporary complexity just as investors are demanding cleaner earnings quality: dilution, integration execution, and reimbursement/channel adoption in diagnostics could keep the stock range-bound even if reported revenue improves. On the competitive side, integrated incumbents in diagnostics and oncology workflow tools may feel pressure sooner than the broad med-tech peer group because distribution embedded in clinical software can shift ordering behavior faster than standalone product launches.

Contrarian view: the consensus may be too focused on the EPS dilution and too little on portfolio quality. If Abbott can cross-sell diagnostics through existing hospital and physician relationships, the acquisition could become a higher-return capital deployment than the market currently prices, especially if the company’s dividend and buyback profile continue to support downside. In that scenario, this is more of a delayed re-rating story than a simple safe-haven healthcare trade.

Key Decisions for Investors

• Initiate a long ABT position on weakness near the recent lows for a 3-6 month horizon; upside case is re-rating toward the prior trading range if integration milestones are met, with downside cushioned by dividend support.
• Buy ABT Jan-2027 calls or call spreads to express the view that the market is underpricing post-integration multiple expansion; use defined risk because the next 1-2 quarters may remain noisy on earnings quality.
• Pair trade: long ABT / short a basket of slower-growth diagnostics or med-tech names with weaker balance sheets over the next 2-4 quarters, targeting relative outperformance if Abbott’s device growth and M&A synergies prove durable.
• If ABT gaps higher on the next catalyst, fade a portion via covered calls rather than outright selling; the stock’s current valuation suggests upside is more likely to come in steps than in a straight line.